SciELO - Scientific Electronic Library Online

 
vol.31 issue1Age above 70 years-old and smoking habit predict the presence of complicated aortic plaques in patients with stroke and no evidence of heart disease author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Revista chilena de cardiología

On-line version ISSN 0718-8560

Abstract

MALUENDA, Gabriel et al. Percutaneous aortic balloon valvuloplasty as a bridge to aortic valve replacement in severe aortic stenosis. Rev Chil Cardiol [online]. 2012, vol.31, n.1, pp.11-17. ISSN 0718-8560.  http://dx.doi.org/10.4067/S0718-85602012000100001.

Background: the recent introduction of percutaneous aortic valve replacement (PAVR) has become a stimulus to perform percutaneous aortic balloon valvu-loplasty (PABV) in patients with severe symptomatic aortic stenosis (AS) as a bridge to valve replacement (AVR) Aim: to determine success rates and clinical results of PABV alone vs those obtained with PABV followed by either surgical or percutaneous AVR. Method: 472 patients with severe AS underwent a total of 538 PABV procedures. 378 (82%) were treated with PABV alone (Group I). In Group II, 85 patients (18%) had PABV followed by either PAVR (n=65) or surgical AVR (n=20). A successful PABV was defined as >40% reduction in mean aortic valve pressure gradient or >40% increase in aortic valve area Results: Groups I and II were comparable regarding age (81.7±8.3 vs. 83.2±10.9 years, p=0.18), STS score (13.1±6.2 vs. 12.4±6.4, p=0.4) and Logistic Euroscore (45.4±22.3 vs. 46.9±21.8, p=0.43). Mean increase in AVA was 0.39±0.25 cm2 in Group I and 0.42±0.26 cm2 in Group II (p=0.33). Mean aortic valve pressure gradient decreased 24.1±13.1 mmHg in Group I and 27 ±1.8 mmHg in Group II (p=0.06). PABV was not successful in 81 patients (15%). As expected, repeated PABV was the main predictor for failure (HR 4.34[95%, CI 2.2-8.3], p<0.001). Midterm mortality rate was 55.2% (214 patients) in Group I and 22.3% (19 patients) in Group II (p<0.001). Intra-pro-cedure mortality was identical in both Groups (2%). Stroke occurred in 2.3% of patients in Group I vs 1.6% in Group II. Conclusion: In high risk patients with severe AS and temporary contraindication for percutaneous or surgical AVR, PABV may be used as a bridge for intervention with good midterm results.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License